Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression
Bipolar II Disorder, Most Recent Episode Major Depressive

About this trial
This is an interventional treatment trial for Bipolar II Disorder, Most Recent Episode Major Depressive focused on measuring Bipolar II Disorder, depression, Lamotrigine, Add On antidepressant, randomized, single blind, parallel group
Eligibility Criteria
Inclusion Criteria:
Subjects who meet all of the following criteria are eligible to participate in this trial:
- Males or females, inpatients or outpatients, aged 17 to 70 years inclusive.
- Diagnosis of Bipolar II Disorder, current episode depressed, without psychotic features. Specifically, patients must have experienced at least one previous episode of hypomania lasting at least 2 days, and no previous manic episodes.
- The current episode of depression has a duration of at least 6 weeks.
- Montgomery-Asberg Depression Rating Scale score of at least 18.
- If female and of child-bearing age, must be using a reliable method of birth control. Reliable methods of birth control include: oral contraceptive pill or patch or surgically implanted device; intra-uterine device (IUD); tubal ligation; barrier device such as diaphragm or condom plus spermicidal jelly or foam; or abstinence.
Exclusion Criteria:
Subjects meeting any of the following criteria are not eligible to participate in the trial:
- Manic or hypomanic symptoms, defined as a YMRS score of 16 or greater.
- Treatment with ECT or a depot antipsychotic medication within eight weeks prior to enrolment; or treatment with an experimental drug within 30 days prior to enrolment.
- Known lack of response to, or intolerance for, Lamotrigine. Lack of response is defined as failure of depressive symptoms to improve after a trial of an acceptable dose of medication, ie. 100 mg daily or greater of Lamotrigine for at least four weeks.
- Depressive symptoms secondary to substance use or a general medical condition, in the opinion of the investigator.
- Diagnosis of an anxiety disorder, including Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Obsessive Compulsive Disorder, Specific Phobia, Post-Traumatic Stress Disorder, or Acute Stress Disorder, which was the primary focus of clinical attention in the year preceding enrolment.
- Diagnosis of Schizophrenia, Schizoaffective Disorder, or Delusional Disorder.
- Substance dependence within one month of enrolment, except for dependence in full remission, and except for caffeine or nicotine dependence, as defined by the DSM-IV-TR.
- Diagnosis of Borderline Personality Disorder, Narcissistic Personality Disorder, Histrionic Personality Disorder, or Antisocial Personality Disorder, which was the primary focus of clinical attention in the year preceding enrolment.
- Significant risk of harm to self or others, in the opinion of the investigator.
- Use of any cytochrome P450 inducer or inhibitor within five half-lives prior to enrolment.
- Pregnancy or lactation in female subjects.
- Unstable or inadequately treated medical illness, as judged by the investigator.
- Liver function tests (AST and ALT) three times the upper limit of normal.
- Glomerular Filtration Rate (GFR) of less than 60 mL/min per 1.73m2
- A history of significant cardiac conduction abnormalities, as determined by the investigator.
Sites / Locations
- University of British Columbia Mood Disorders Centre
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Lamotrigine Plus Antidepressant
2. Lamotrigine Monotherapy
Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.